Explored prognostic factors for survival in patients with advanced GIST treated with standard dose imatinib (IM): Results from the BFR14 phase III trial of the French Sarcoma Group.
David Pérol
Honoraria - Roche
Isabelle Ray-Coquard
Honoraria - Amgen; Merck; Novartis; PharmaMar; Roche; Sanofi
Research Funding - Merck (B); Novartis; Roche
Binh Bui Nguyen
Honoraria - Novartis; PharmaMar
Antoine Adenis
No relevant relationships to disclose
Maria Rios
No relevant relationships to disclose
François Bertucci
No relevant relationships to disclose
Florence Duffaud
No relevant relationships to disclose
Didier Cupissol
No relevant relationships to disclose
Christine Chevreau
No relevant relationships to disclose
Emmanuelle Bompas
No relevant relationships to disclose
Julien Domont
No relevant relationships to disclose
Sylvie Chabaud
No relevant relationships to disclose
Jean-Yves Blay
Honoraria - GlaxoSmithKline; Novartis; Pfizer; PharmaMar; Roche
Research Funding - GlaxoSmithKline; Novartis; Pfizer; PharmaMar; Roche
Axel Le Cesne
Honoraria - Novartis; Pfizer; PharmaMar